Medically reviewed by Nicholas R. Metrus, MD Multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease) are both diseases that affect your central nervous system ...

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | ...

A Jacksonville woman's experience caring for her husband with ALS has formed a foundation to help other families fighting ...

Researchers genetically reprogrammed mouse nerve cells to reverse cell aging, delaying the onset of ALS symptoms in the animals.

SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, with an incidence of 1 or 2 cases per 100,000 persons and a lifetime risk of 1 case per 800 persons.